Publisher
Springer International Publishing
Reference21 articles.
1. Chatal JF, Hoefnagel CA. Radionuclide therapy. Lancet. 1999;354(9182):931–5.
2. Zukotynski K, Jadvar H, Capala J, Fahey F. Targeted radionuclide therapy: practical applications and future prospects. Biomark Cancer. 2016;8(Suppl 2):35–8.
3. Wagner HN Jr, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, Lamonica DM, Conti PS. Administration guidelines for radioimmunotherapy of non-Hodgkin’s lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43(2):267–72.
4. Iagaru A, Mittra ES, Ganjoo K, Knox SJ, Goris ML. 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma. Mol Imaging Biol. 2010;12(2):198–203.
5. Chatal JF, Kraeber-Bodere F, Barbet J. Consolidation radioimmunotherapy of follicular lymphoma: a step towards cure? Eur J Nucl Med Mol Imaging. 2008;35(7):1236–9.